2015, Volume 8, Issue 4, pp 548 – 551

Clozapine and risperidone influence on cortisol and estradiol levels in male patients with schizophrenia

SCImago Journal & Country Rank

Issues

Special Issues

Authors and Affiliations

Correspondence to: Stoian I, MD “Carol Davila” University of Medicine and Pharmacy, Bucharest 8 Eroilor Sanitari Blvd., District 5, code 050474, Bucharest, Romania Mobile phone: +40748 038 284, E-mail: irina_stoian64@yahoo.com

Abstract

Estrogens role in schizophrenia patients is a subject, which has gained an increased attention from the medical community. Estrogens have been shown to inhibit dopamine actions, improve neuronal regeneration, and overall, have a protective role in the pathology of schizophrenia. The adjunctive estrogen therapy for men is currently under debate.

Antipsychotic medication is known to influence the hypothalamo-hypophyseal – gonadal axis by inducing variable degrees of hyperprolactinemia. Several studies have found that some of the atypical antipsychotics lower cortisol levels in patients and also in healthy controls.

We have investigated the effects of clozapine and risperidone on estradiol levels in men with schizophrenia. We have also evaluated the levels of prolactin and cortisol, taking into account the possible influence of antipsychotic drugs on both these hormones. Both prolactin and cortisol also have the potential to regulate sexual hormones biosynthesis.

Our study found decreased estradiol levels in men with schizophrenia treated with clozapine and risperidone, while prolactin levels were increased only in the risperidone treated group. Cortisol levels are not statistically significant different between groups.

Keywords

About this article

PMC ID: 4656970
PubMed ID: 26664488
DOI: 

Article Publishing Date (print): Oct-Dec 2015
Available Online: 

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.


SCImago Journal & Country Rank

Issues

Special Issues